Lofexidine for Opiate Withdrawal - 1
- Conditions
- Opioid-Related Disorders
- Registration Number
- NCT00032942
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to evaluate lofexidine for opiate withdrawal.
- Detailed Description
An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted in inpatient units at 3 treatment sites.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
Male or female as least 18 yrs of age & above with a current dependence on heroin, morphine or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent and signed informed consent; females using appropriate birth control method.
Additional criteria available during screening at the site
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Opiate withdrawal symptoms Potential Abuse Liability
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Philadelphia Veterans Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
UCLA Medical Center
🇺🇸Los Angeles, California, United States
Columbia University
🇺🇸New York, New York, United States